IBP-9414

Phase 3Small molecule

IInfant Bacterial Therapeutics

IBP-9414 is one of 17 small molecule programs targeting Necrotizing Enterocolitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Necrotizing EnterocolitisActive, not recruiting

Necrotizing EnterocolitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Necrotizing Enterocolitis

#DrugCompanyPhaseTrials

N-Acetyl Cyteien

SStanford University

Approved

1 2

Trental

VValidus Pharmaceuticals

Phase 3

1 3

Lumason

BBracco Diagnostics, Inc

Phase 3

1 4

Lactobacillus Reuteri

TTulane University School of Medicine

Phase 3

1 5

Saccharomyces Boulardii

BBiocodex

Phase 3

1 6

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 1

2 7

Cafcit

KKaken Pharmaceutical

Phase 1

1 8

Amikin

IInsmed Incorporated

Phase 1

1 9

ST266

NNoveome Biotherapeutics, formerly Stemnion

Phase 2

1 10

IBP-9414

IInfant Bacterial Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Necrotizing Enterocolitis2 trials

IBP-9414 for the Prevention of Necrotizing Enterocolitis

Completed·IInfant Bacterial Therapeutics·Phase 2·NCT02472769·120 enrolled

IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Active, not recruiting·IInfant Bacterial Therapeutics·Phase 3·NCT03978000·2,158 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IBP-9414. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IBP-9414 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IBP-9414. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Infant Bacterial Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInfant Bacterial Therapeutics

IBP-9414

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Necrotizing Enterocolitis2 trials

References

Drug Info

Quick Facts

Related News